RE:RE:RE:RE:RE:RE:RE:RE:Cash burn at AEZSTencents wrote: And why did aeterna not sell it to someone for 100 plus M $
If AEZS's assets are really worth >$150 million and this is a merger of equals CZO is also being valued at >$150 million. Together it could be a >$300 million deal in perceived value. Together with a footprint in Europe and North America they could enter stronger PGX deals, etc., further increasing value and pursue opportunities on their own.
The yeast beta glucan market is worth $1 billion. The CoQ10 market is worth $4 billin Gilles has said. CZO may have the gold standard in these markets and broader applicability. Dr. Martin Kolb said PGX-YBG could profoundly change the treatment landscape for fibrosis. At the AGM Gilles said they were in talks with serious companies concerning a licensing deal. AEZS is in discussions of its own concerning re-licenisng the growth hormone deficiency test and has been speaking to regulators about the path forward concerning another opportunity. Gilles and AEZS have a long-standing relationship and being on the inside of AEZS Gilles should have an appreciation for how the business is evolving concerning deals, and regulatory parameters for other assets, and concerning the launch of the testi n Europe, etc. Now is the time to move it appears as a number of catalysts approach.